Page 1327 - Williams Hematology ( PDFDrive )

1302 Part X: Malignant Myeloid Diseases Chapter 84: Polycythemia Vera 1303

18. Prchal JF, Adamson JW, Steinmann L, et al: Human erythroid colony formation in vitro: 51. Wang L, Swierczek SI, Drummond J: Whole-exome sequencing of polycythemia vera
Evidence for clonal origin. J Cell Physiol 89(3):489–492, 1976. revealed novel driver genes and somatic mutation shared by T cells and granulocytes.
19. Groopman JE: The pathogenesis of myelofibrosis in myeloproliferative disorders. Ann 28(4):935–938, 2014.
Intern Med 92(6):857–858, 1980. 52. Wang L, Swierczek SI, Lanikova L, et al: The relationship of JAK2(V617F) and acquired
20. Moliterno AR, Hankins WD, Spivak JL: Impaired expression of the thrombopoie- UPD at chromosome 9p in polycythemia vera. Leukemia 28(4):938–941, 2014.
tin receptor by platelets from patients with polycythemia vera. N Engl J Med 338(9): 53. Spivak JL, Considine M, Williams DM, et al: Two clinical phenotypes in polycythemia
572–580, 1998. vera. N Engl J Med 371(9):808–817, 2014.
21. Silva M, Richard C, Benito A, et al: Expression of Bcl-x in erythroid precursors from 54. Olcaydu D, Harutyunyan A, Jager R, et al: A common JAK2 haplotype confers suscep-
patients with polycythemia vera. N Engl J Med 338(9):564–571, 1998. tibility to myeloproliferative neoplasms. Nat Genet 41(4):450–454, 2009.
22. Sui X, Krantz SB, Zhao Z: Identification of increased protein tyrosine phosphatase 55. Olcaydu D, Skoda RC, Looser R, et al: The “GGCC” haplotype of JAK2 confers suscep-
activity in polycythemia vera erythroid progenitor cells. Blood 90(2):651–657, 1997. tibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia 23(10):1924–
23. James C, Ugo V, Le Couedic JP, et al: A unique clonal JAK2 mutation leading to consti- 1926, 2009.
tutive signalling causes polycythaemia vera. Nature 434(7037):1144–1148, 2005. 56. Kilpivaara O, Mukherjee S, Schram AM, et al: A germline JAK2 SNP is associated with
24. Bench AJ, Nacheva EP, Champion KM, et al: Molecular genetics and cytogenetics of predisposition to the development of JAK2(V617F)-positive myeloproliferative neo-
myeloproliferative disorders. Baillieres Clin Haematol 11(4):819–848, 1998. plasms. Nat Genet 41(4):455–459, 2009.
25. Diez-Martin JL, Graham DL, Petitt RM, et al: Chromosome studies in 104 patients with 57. Jones AV, Chase A, Silver RT, et al: JAK2 haplotype is a major risk factor for the devel-
polycythemia vera. Mayo Clin Proc 66(3):287–299, 1991. opment of myeloproliferative neoplasms. Nat Genet 41(4):446–449, 2009.
26. Green A, Campbell P, Buck G, et al: The Medical Research Council PT1 Trial in Essen- 58. Delhommeau F, Dupont S, Della Valle V, et al: Mutation in TET2 in myeloid cancers.
tial Thrombocythemia. Blood 104(Suppl 1):5a, 2004. N Engl J Med 360(22):2289–2301, 2009.
27. Najfeld V, Montella L, Scalise A, et al: Exploring polycythaemia vera with fluorescence 59. Tefferi A, Pardanani A, Lim KH, et al: TET2 mutations and their clinical correlates
in situ hybridization: Additional cryptic 9p is the most frequent abnormality detected. in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia
Br J Haematol 119(2):558–566, 2002. 23(5):905–911, 2009.
28. Wurster-Hill D, Whang-Peng J, McIntyre OR, et al: Cytogenetic studies in polycythe- 60. Saint-Martin C, Leroy G, Delhommeau F, et al: Analysis of the ten-eleven translocation
mia vera. Semin Hematol 13(1):13–32, 1976. 2 (TET2) gene in familial myeloproliferative neoplasms. Blood 114(8):1628–1632, 2009.
29. Sever M, Quintas-Cardama A, Pierce S, et al: Significance of cytogenetic abnormalities 61. Busque L, Patel JP, Figueroa ME, et al: Recurrent somatic TET2 mutations in normal
in patients with polycythemia vera. Leuk Lymphoma 54(12):2667–2670, 2013. elderly individuals with clonal hematopoiesis. Nat Genet 44(11):1179–1181, 2012.
30. Swolin B, Weinfeld A, Westin J: A prospective long-term cytogenetic study in poly- 62. Cazzola M, Kralovics R: From Janus kinase 2 to calreticulin: The clinically relevant
cythemia vera in relation to treatment and clinical course. Blood 72(2):386–395, 1988. genomic landscape of myeloproliferative neoplasms. Blood 123(24):3714–3719, 2014.
31. Spivak JL: Polycythemia vera: Myths, mechanisms, and management. Blood 63. Wang L, Swierczek SI, Drummond J, et al: Whole-exome sequencing of polycythemia
100(13):4272–4290, 2002. vera revealed novel driver genes and somatic mutation shared by T cells and granulo-
32. Baxter EJ, Scott LM, Campbell PJ, et al: Acquired mutation of the tyrosine kinase JAK2 cytes. Leukemia 28(4):935–938, 2014.
in human myeloproliferative disorders. Lancet 365(9464):1054–1061, 2005. 64. Li S, Kralovics R, De Libero G, et al: Clonal heterogeneity in polycythemia vera patients
33. Kralovics R, Passamonti F, Buser AS, et al: A gain-of-function mutation of JAK2 in with JAK2 exon12 and JAK2-V617F mutations. Blood 111(7):3863–3866, 2008.
myeloproliferative disorders. N Engl J Med 352(17):1779–1790, 2005. 65. Kristinsson SY, Landgren O, Samuelsson J, et al: Autoimmunity and the risk of myelo-
34. Levine RL, Wadleigh M, Cools J, et al: Activating mutation in the tyrosine kinase JAK2 proliferative neoplasms. Haematologica 95(7):1216–1220, 2010.
in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelo- 66. Hasselbalch HC: Perspectives on chronic inflammation in essential thrombocythemia,
fibrosis. Cancer Cell 7(4):387–397, 2005. polycythemia vera, and myelofibrosis: Is chronic inflammation a trigger and driver of
35. Jelinek J, Oki Y, Gharibyan V, et al: JAK2 mutation 1849G>T is rare in acute leukemias clonal evolution and development of accelerated atherosclerosis and second cancer?
but can be found in CMML, Philadelphia chromosome-negative CML, and megakary- Blood 119(14):3219–3225, 2012.
ocytic leukemia. Blood 106(10):3370–3373, 2005. 67. Hasselbalch HC: Chronic inflammation as a promotor of mutagenesis in essential
36. Jones AV, Kreil S, Zoi K, et al: Widespread occurrence of the JAK2 V617F mutation in thrombocythemia, polycythemia vera and myelofibrosis. A human inflammation
chronic myeloproliferative disorders. Blood 106(6):2162–2168, 2005. model for cancer development? Leuk Res 37(2):214–220, 2013.
37. Nussenzveig RH, Swierczek SI, Jelinek J, et al: Polycythemia vera is not initiated by 68. Hasselbalch HC: A role of NF-E2 in chronic inflammation and clonal evolution in essential
JAK2V617F mutation. Exp Hematol 35(1):32–38, 2007. thrombocythemia, polycythemia vera and myelofibrosis? Leuk Res 38(2):263–266, 2014.
38. Tefferi A, Lasho TL, Schwager SM, et al: The clinical phenotype of wild-type, hete- 69. Skov V, Larsen TS, Thomassen M, et al: Molecular profiling of peripheral blood cells
rozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 106(3):631–635, from patients with polycythemia vera and related neoplasms: Identification of deregu-
2006. lated genes of significance for inflammation and immune surveillance. Leuk Res
39. Passamonti F, Rumi E, Pietra D, et al: A prospective study of 338 patients with poly- 36(11):1387–1392, 2012.
cythemia vera: The impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic 70. Berlin NI: Diagnosis and classification of the polycythemias. Semin Hematol 12(4):339–
or leukemic disease transformation and vascular complications. Leukemia 24(9):1574– 351, 1975.
1579, 2010. 71. Marchioli R, Finazzi G, Landolfi R, et al: Vascular and neoplastic risk in a large cohort
40. Silver RT, Vandris K, Wang YL, et al: JAK2(V617F) allele burden in polycythemia vera of patients with polycythemia vera. J Clin Oncol 23(10):2224–2232, 2005.
correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk 72. Falanga A, Marchetti M: Thrombotic disease in the myeloproliferative neoplasms.
Res 35(2):177–182, 2011. Hematology Am Soc Hematol Educ Program 2012:571–581, 2012.
41. Alvarez-Larran A, Bellosillo B, Pereira A, et al: JAK2V617F monitoring in polycythe- 73. Falanga A, Marchetti M: Thrombosis in myeloproliferative neoplasms. Semin Thromb
mia vera and essential thrombocythemia: Clinical usefulness for predicting myelofi- Hemost 40(3):348–358, 2014.
brotic transformation and thrombotic events. Am J Hematol 89(5):517–523, 2014. 74. Wehmeier A, Daum I, Jamin H, et al: Incidence and clinical risk factors for bleeding
42. Koren-Michowitz M, Landman J, Cohen Y, et al: JAK2V617F allele burden is associated and thrombotic complications in myeloproliferative disorders. A retrospective analysis
with transformation to myelofibrosis. Leuk Lymphoma 53(11):2210–2213, 2012. of 260 patients. Ann Hematol 63(2):101–106, 1991.
43. Kuriakose E, Vandris K, Wang YL, et al: Decrease in JAK2 V617F allele burden is not 75. Landolfi R, Marchioli R, Kutti J, et al: Efficacy and safety of low-dose aspirin in poly-
a prerequisite to clinical response in patients with polycythemia vera. Haematologica cythemia vera. N Engl J Med 350(2):114–124, 2004.
97(4):538–542, 2012. 76. Berk PD, Goldberg JD, Donovan PB, et al: Therapeutic recommendations in poly-
44. Scott LM, Tong W, Levine RL, et al: JAK2 exon 12 mutations in polycythemia vera and cythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol
idiopathic erythrocytosis. N Engl J Med 356(5):459–468, 2007. 23(2):132–143, 1986.
45. Scott LM: The JAK2 exon 12 mutations: A comprehensive review. Am J Hematol 77. Polycythemia vera: The natural history of 1213 patients followed for 20 years. Gruppo
86(8):668–676, 2011. Italiano Studio Policitemia. Ann Intern Med 123(9):656–664, 1995.
46. Passamonti F, Elena C, Schnittger S, et al: Molecular and clinical features of the myelo- 78. Berk P, Wasserman L, Fruchtman S: Treatment of polycythemia vera. A summary of
proliferative neoplasm associated with JAK2 exon 12 mutations. Blood 117(10):2813– clinical trials conducted by the Polycythemia Study Group, in Polycythemia Vera and
2816, 2011. the Myeloproliferative Disorders, edited by Wasserman L, Berk P, Berlin N. WB Saun-
47. Skoda R, Prchal JT: Lessons from familial myeloproliferative disorders. Semin Hematol ders, Philadelphia, 1995.
42(4):266–273, 2005. 79. Coucelo M, Caetano G, Sevivas T, et al: JAK2V617F allele burden is associated with
48. Cario H, Schwarz K, Herter JM, et al: Clinical and molecular characterisation of a pro- thrombotic mechanisms activation in polycythemia vera and essential thrombocythe-
spectively collected cohort of children and adolescents with polycythemia vera. Br J mia patients. Int J Hematol 99(1):32–40, 2014.
Haematol 142(4):622–626, 2008. 80. Carobbio A, Finazzi G, Antonioli E, et al: JAK2V617F allele burden and thrombosis: A
49. Kralovics R, Teo SS, Buser AS, et al: Altered gene expression in myeloproliferative dis- direct comparison in essential thrombocythemia and polycythemia vera. Exp Hematol
orders correlates with activation of signaling by the V617F mutation of Jak2. Blood 37(9):1016–1021, 2009.
106(10):3374–3376, 2005. 81. Spivak JL, Barosi G, Tognoni G, et al: Chronic myeloproliferative disorders. Hematology
50. Theocharides A, Boissinot M, Girodon F, et al: Leukemic blasts in transformed Am Soc Hematol Educ Program 200–224, 2003.
JAK2-V617F-positive myeloproliferative disorders are frequently negative for the 82. Barbui T, Finazzi G: Special issues in myeloproliferative neoplasms. Curr Hematol Malig
JAK2-V617F mutation. Blood 110(1):375–379, 2007. Rep 6(1):28–35, 2011.

Kaushansky_chapter 84_p1291-1306.indd 1302 9/21/15 11:11 AM